On bivariate time-varying price staleness

Price staleness refers to the extent of zero returns in price dynamics. Bandi et al. (2020c) introduce two types of staleness: systematic and idiosyncratic staleness. In this study, we allow price staleness to be time-varying and study the statistical inference for idiosyncratic and common price staleness between two assets. We propose consistent estimators for both time-varying idiosyncratic and systematic price staleness and derive their asymptotic theory. Moreover, we develop a feasible nonparametric test for the simultaneous constancy of idiosyncratic and common price staleness. Our inference is based on infill asymptotics. Finally, we conduct simulation studies under various scenarios to assess the finite sample performance of the proposed approaches and provide an empirical application of the proposed theory.</p

Additional file 2 of Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Additional file 2: Table S1.Baseline characteristics by participant site. Table S2.Multivariate analyses of recurrence-free survival in total population (Cox model). Table S3.Multivariate analyses of overall survival in total population (Cox model). Table S4.Interaction between preoperative CEA and CA19-9 with risk of outcomes. Table S5.Multivariate analyses of recurrence-free survival in colorectal cancer subgroup with CEA < 5 ng/ml (Cox model). Table S6.Multivariate analyses of recurrence-free survival in colorectal cancer subgroup with CEA ≥ 5 ng/ml (Cox model). Table S7. Multivariate analyses of overall survival in colorectal cancer subgroup with CEA < 5 ng/ml (Cox model). Table S8.Multivariate analyses of overall survival in colorectal cancer subgroup with CEA ≥ 5 ng/ml (Cox model). Table S9.A frailty model analysis of preoperative CA19-9 (cutoff: 37 U/ml) on colorectal cancer outcomes in total population. TableS10.Cox proportional hazard regression analysis of preoperative CA19-9 (cutoff:74 U/ml) on colorectal cancer outcomes in total population. Table S11.Relationship between preoperative CA19-9 and benefit from adjuvant chemotherapyin patients with stage II colorectal cancer

Additional file 1 of Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Additional file 1: FigureS1. Association between preoperative CA19-9 status and overall survival. (a) overall population. (b) patients with normal preoperative CEA. (c) patientswith elevated preoperative CEA. Solid yellow lines are unadjustedhazard ratios, with dashed yellow lines showing 95% confidence intervalsderived from restricted cubic spline regressions. Reference lines for noassociation are indicated by the solid bold lines at a hazard ratio (HR) of 1.0. Dashed blue curves show the fraction of the population with different levels of preoperative CA19-9. Arrows indicate the concentration of preoperative CA19-9 with HR of 1.0. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; E, number of events; HR, hazard ratio; N, number of patients. FigureS2. Kaplan‐Meier curves for overall survival according to the preoperative CA19-9 group. (a) overall population. (b) patients with normal preoperative CEA. (c) patientswith elevated preoperative CEA. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen. FigureS3. Kaplan‐Meier curves according to the joint group of preoperative CEA and CA19-9 in colorectal cancer patients. (a) recurrence-free survival. (b) overall survival. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; OS, overall survival; RFS, recurrence-free survival. FigureS4. Forest plot for recurrence-free survival of preoperative CA 19-9 groups stratified by clinicopathological features based on the Cox models. P values for interaction were calculated using Cox regression model. HR and 95%CIs were given and visually represented by the squares and error bars. CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio. FigureS5. Forest plot for performance overallsurvival of preoperative CA19-9 groups stratified by clinicopathological features based on the Cox models. P values for interaction were calculated using Cox regression model. HR and 95%CIs were given and visually represented by the squares and error bars. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidenceinterval; HR, hazard ratio. FigureS6. Kaplan‐Meier curves according to the joint group of preoperative CEA and CA19-9 in patients with stage II colorectal cancer. (a) recurrence-free survival.(b) overall survival. CA 19-9, carbohydrate antigen 19-9;CEA, carcinoembryonic antigen; OS, overall survival; RFS, recurrence-freesurvival